SecBot SecBot
8-K ·Filed Jun 4, 2026

BMRN

BIOMARIN PHARMACEUTICAL INC
NEUTRAL
Impact 2/10
Horizonimmediate Processed5mo ago SEC0001628280-26-040812
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine annual meeting results with no earnings or guidance implications. The equity plan amendment adds modest potential dilution (~4% of shares outstanding) but is standard practice. No trading action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$56.77
T+0 close · Jun 4, 2026 · via day close
Latest settled
+14.28%
T+60 · $64.87
Vs SPY
+10.28%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 5 $56.77entry
  2. T+1 · 5mo ago −0.39%α −0.61% · $56.55
  3. T+5 · 5mo ago −1.44%α −2.01% · $55.95
  4. T+20 · 4mo ago +3.56%α +1.70% · $58.79
  5. T+60 · 3mo ago +14.28%α +10.28% · $64.87

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BioMarin filed an 8-K reporting results from its 2026 Annual Meeting of Stockholders. Shareholders approved all four proposals, including the election of ten director nominees, ratification of KPMG as auditor, an advisory vote on executive compensation, and an amendment to the 2017 Equity Incentive Plan to increase the share reserve by 7,650,000 shares. This is a routine administrative filing with no material financial impact.

Key Facts

  • Shareholders approved an amendment to the 2017 Equity Incentive Plan, increasing the share reserve by 7,650,000 shares.
  • All ten director nominees were elected with strong majority support.
  • KPMG LLP was ratified as independent auditor for fiscal year 2026.
  • Advisory vote on named executive officer compensation passed with ~87% of votes cast in favor.
  • 193,270,028 shares were entitled to vote; 175,813,292 shares were present or represented at the meeting.

Financial Impact

No financial figures reported; equity plan amendment adds 7,650,000 shares to the reserve, representing approximately 3.96% of outstanding shares based on 193,270,028 shares entitled to vote.

dilution

Risk Factors

  • Potential future dilution from equity awards granted under the amended plan.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (34 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-040812
Document: 0001628280-26-040812-index-headers.html0001628280-26-040812
Document: 0001628280-26-040812-index.html0001628280-26-040812
Document: 0001628280-26-040812.txt0001628280-26-040812

Track record

16 reports on BMRN

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +8.91% at T+60 after the Apr 27, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 4, 202612d ago SC 13G/A Neutral 3/10 Entry $56.12 to $56.70 Now $57.99 +3.33% ▲ +1.03% −2.26% vs SPY
  2. Nov 2, 202614d ago 8-K Bearish 6/10 Entry $55.66 to $57.13 Now $57.99 −4.19% ▼ −2.64% −3.23% vs SPY
  3. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $57.49 to $56.12 Now $57.99 +0.87% ▼ −2.38% +2.34% vs SPY
  4. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $56.00 to $57.13 Now $57.99 +3.55% ▲ +2.02% +2.73% vs SPY
  5. Oct 6, 20265w ago 8-K Bearish 6/10 Entry $55.20 to $55.14 Now $57.99 −5.05% ▲ +0.11% −0.87% vs SPY
  6. Sep 15, 20268w ago 8-K Neutral 4/10 Entry $64.45 to $63.94 Now $57.99 −10.02% ▼ −0.79% −1.61% vs SPY
  7. Sep 14, 20269w ago 8-K Neutral 2/10 Entry $66.41 to $64.06 Now $57.99 −12.68% ▼ −3.54% −3.65% vs SPY
  8. Sep 1, 202610w ago 8-K Neutral 3/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
  9. Sep 1, 202610w ago Press Release Neutral 4/10 Entry $64.84 to $64.41 Now $57.99 −10.56% ▼ −0.66% −0.74% vs SPY
  10. Aug 31, 202611w ago 8-K Bullish 6/10 Entry $65.23 to $64.63 Now $57.99 −11.10% ▼ −0.92% −0.78% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens Wed (10h 49m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 4, 2026